Review 111

Analysis of community-based studies related with knowledge, awareness, attitude, and behaviors towards HPV and HPV vaccine published in Turkey: A systematic review

¹Department of Public Health Nursing, University of Health Sciences Turkey, Gülhane Faculty of Nursing, Ankara, Turkey ²Department of Obstetrics and Gynecology, University of Health Sciences Turkey, Gülhane Training and Research Hospital, Ankara, Turkey

Abstract

Human papilloma virus (HPV) vaccine is a proven method for preventing HPV-related cancers and genital warts, especially preventing cervical cancer. It is aimed to systematically review and synthesize conclusions in detail from community-based studies published in Turkey between 2009 and 2019, which evaluate the knowledge, awareness, attitude, and behaviors of individuals towards HPV and HPV vaccination. This systematic review is conducted based on the PRISMA reporting method and includes community-based, descriptive cross-sectional and cross-sectional studies published between 2009 and 2019. In this systematic review, 5132 studies from six databases were scanned in total. It was determined that there were 23 studies that met the eligibility criteria for this systematic review. In the reviewed studies, it was determined that the rate of "Hearing of HPV before" was 3.8% at the lowest and 57.0% at the highest, and the rate of "Hearing of HPV vaccine before" was 2.2% at the lowest and 74.7% at the highest. In the reviewed studies, it was reported that although parents' willingness to have their daughters vaccinated with HPV vaccine varied between 14.4% and 68.0%, their willingness to have their sons vaccinated with HPV vaccine varied between 11.0% and 62.0%. In addition, it was reported that the lowest rate of vaccination with HPV vaccine among participants was 0.3% at the lowest and 6.0% at the highest. Consequently, it is considered that conducting common, systematic, and continuous health education programs aimed at both sexes and including both parents, which will increase the knowledge and awareness on HPV and its vaccine, would provide positive attitudes, and will be effective in protecting against HPV-related cancers. (J Turk Ger Gynecol Assoc 2020; 21: 111-23)

Keywords: Human papilloma virus, HPV vaccine; knowledge, awareness, attitude, public health

Received: 16 April, 2019 Accepted: 29 July, 2019

Introduction

Human papilloma virus (HPV) infection, which is sexually transmitted to both males and females, is a global epidemic (1-3). Approximately 75% of sexually active individuals encounter HPV at some time in their lives (4). Thirteen known carcinogenic types of HPV, which have approximately 200 diagnosed types, may become cancerous by causing chronic and progressive infection (5). HPV-related cancers are listed as cervical, vulvar, vaginal, anal, rectal, penile, and oropharyngeal cancers (5,6).

According to data from the surveillance program conducted by the Centers for Disease Control and Prevention in the United States of America between 2008-2012, it is reported that 38,793 people on average were diagnosed as having HPV-related cancer and 59% of whom were females and 41% were males (6). In the last five years in Turkey, the reported prevalences of cervical cancer, vulvar cancer, anal cancer and penile cancer were 16.09%, 1.82%, 1.09%, and 0.16%, respectively (7).

HPV vaccine is a proven method for preventing HPV-related cancers and genital warts, especially preventing cervical cancer



(8,9). It is reported that vaccines containing HPV16-18 types prevent 63% of all HPV-related cancers; vaccines containing nine types of HPV (HPV6-11-16-18-31-33-45-52-58) provide protection against cervical, vulvar, vaginal, and anal cancers by 90% (6,10). Throughout the world and in Turkey, HPV vaccines are recommended to individuals from both sexes between the ages of 9 and 26 years and before the first sexual experience (11,12). The HPV vaccine, the safety of which has been verified by the European Medicines Agency (13), is included in national vaccination program in many countries, but it is not included in Turkey's national vaccination schedule (13-15).

Objectives

The literature reported that negative attitude and behaviors of individuals and parents such as lack of knowledge and low awareness about mode of transmission, protection, and early diagnosis methods of HPV infection, cost of HPV vaccine, potential adverse effects, and suspecting vaccine safety, and negative news on all vaccines prevented the generalization of the HPV vaccination (16-18). In the current study, the aim was to systematically review community-based studies that evaluated the knowledge, awareness, attitude, and behaviors of individuals towards HPV and HPV vaccine published in Turkey between 2009 and 2019, and the available conclusions were synthesized in detail.

Protocol and registration

This systematic review was registered on the International Prospective Register of Systematic Reviews system (approval number: 128435). This systematic review was conducted based on PRISMA reporting method and includes community-based, descriptive cross-sectional and cross-sectional studies published between 2009 and 2019.

Eligibility criteria

The investigated studies, which were about protection methods against cervical cancer in Turkey published in the last 10 years, were focused on individuals' knowledge, awareness, attitude, and behaviors on HPV and HPV vaccine. In the literature, no systematical national research report was found on individuals' knowledge, awareness, attitude, and behaviors on HPV and the HPV vaccine (2). In this systematic review, it was decided that synthesizing community-based studies would be appropriate by anticipating that they would reflect the current status of the community at risk in terms of HPV infection in Turkey. In this respect, eligibility criteria were based on the literature as follows: (1) descriptive cross-sectional and cross-sectional research design published in a national or international peer-reviewed journal; (2) conducted within the borders of the

Republic of Turkey; (3) published between 2009 and 2019; (4) sample consisting of healthy/sick individuals. Review articles, letters to the editor, qualitative studies, case-control studies, congress proceedings, and theses were excluded from the systematic review.

Information sources

Studies included in the systematic review were obtained as a result of comprehensive review of EBSCO, Google Scholar, Proquest, PubMed, Springer, and TR index databases between March 1st and 4th, 2019.

Search

Keywords in English used in the review were "Turkey", "HPV", "Human Papilloma Virus", "HPV vaccine", "knowledge", "awareness", "attitudes", "behavior"; and "Türkiye", "İnsan Papilloma Virüsü", "Human Papilloma Virüsü", "HPV aşısı", "bilgi", "farkındalık", "tutum" and "davranış" words were used in the Turkish database.

Study selection

In this systematic review, as a result of comprehensive scanning of the databases, 118 research reports were identified according to the titles and abstracts that met the eligibility criteria. It was observed that there were 43 recurring studies among this research. In the assessment according to title and abstract after the recurring researches were identified, studies conducted by healthcare professionals/students (n=47), intervention studies (n=3), scale validity reliability studies (n=2), and studies conducted on immigrant Turks (n=1)were eliminated because they did not fit the purpose of the systematic review. After this stage, the full texts of the studies were reviewed (n=25). Studies for which the full text was not available were excluded from the systematic review (n=2). Following the assessments, it was determined that there were 23 studies that met the eligibility criteria for this systematic review (Figure 1).

Data collection process

Evidence centers such as the Cochrane Library and Joanna Briggs Institute (JBI) recommend that the studies addressed in systematic reviews are assessed using standardized critical instruments to determine their scientific value and bias risk according to their objectives, design, and method properties (19). It is reported that valid and reliable instruments for determining the reporting quality of cross-sectional studies are limited (20). To assess the reporting quality and properties of the 23 studies included in this systematic review, the 8-question

JBI-Critical Appraisal Checklist for Analytical Cross-sectional Studies, which was developed by JBI, was used (21). In the check list, the quality of the studies was assessed in each question as "1=yes", "2=no", "3=unclear", "4=not applicable" (Table 1).

A data collection form developed by the researchers based on the literature was used to collect the data of the scanned studies included in the systematic review. The data collection form includes the author, year, subject, location, sample size and properties, method, main findings, conclusion, and suggestion titles of the study. Researchers reviewed the full texts of 23 studies in detail and recorded in the data collection form under titles independently from each other. Data collection forms of each study were reviewed by all researchers and the data of the systematic review were established.

Data items

The collected data was merged under the titles of "Author", "Year", "Location of the Research", "Age Range", "Health




Figure 1. PRISMA flow diagram of the systematic review

Table 1. Joanna Briggs Institute-critical appraisal checklist for analytical cross-sectional studies (n=23)

	Yes		No		Uncle	ear	Not appli	cable
	n	%	n	%	n	%	n	%
1. Were the criteria for inclusion in the sample clearly defined?	22	95.6	1	4.3	-	-	-	-
2. Were the study subjects and the setting described in detail?	13	56.5	9	39.1	1	4.3	-	-
3. Was the exposure measured in a valid and reliable way?	1	4.3	22	95.6	-	-	-	-
4. Were objective, standard criteria used for the measurement of the condition?	23	100	-	-	-	-	-	-
5. Were confounding factors identified?	4	17.3	19	82.6	-	-	-	-
6. Were strategies for dealing with confounding factors stated?	4	17.6	19	82.6	-	-	-	-
7. Were the outcomes measured in a valid and reliable way?	23	100	-	-	-	-	-	-
8. Was appropriate statistical analysis used?	23	100	-	-	-	-	-	-

Center", "Number of Participants", "Properties of Sample", "Hearing of HPV", "Hearing of HPV vaccine", "Vaccination Rate", "Willingness to Vaccination for Own Self", "Willingness to Vaccination for Daughter", "Willingness to Vaccination for Son", "Barriers of HPV Vaccine", "Source of HPV Knowledge", "Willingness to have Education about HPV", "Factors in relation to HPV and Vaccine Knowledge" and "Suggestions" (Table 2, 3).

Study selection

In this systematic review, 5132 studies from six databases were scanned in total. It was determined that there were 43 recurring studies out of 118 studies identified according to the titles and abstracts. Number of identified studies was determined as 78. Fifty-four studies that were determined to be beyond the purpose of the systematic review based on the title and abstract were eliminated. Out of the 25 studies whose full texts were to be assessed for eligibility, two studies were excluded because their full texts were not available. The full texts of 23 studies that met the eligibility criteria were included in the scope of the systematic review (Figure 1).

Reporting characteristics of studies

In the assessment of the studies according to the JBI-Critical Appraisal Checklist for Analytical Cross-sectional Studies, it was determined that eligibility criteria were defined clearly in the sample in 95.6% (n=22) of the studies, and the study subject and methods were explained in detail in 56.5% (n=13) of the studies. It was observed that the researched case was measured in a valid and reliable manner in only 4.3% (n=1) of the studies included in the systematic review, but all of the studies (n=23) used objective criteria for measuring the researched case. It was determined that confounding factors were not identified in 82.6% (n=19) of the studies, and also strategies for coping with confounding factors were not specified. It was determined that the results of all studies (n=23) were assessed using objective criteria and suitable statistical analyses were conducted (Table 1).

Study characteristics

It was determined that 56.5% (n=13) of the studies included in the systematic review were published between 2009 and 2013 and 56.5% (n=13) were published in international indexed journals. In the studies that were assessed, the age range of the participants varied between 13 and 87 years. The number of participants in the studies was between 229 and 1808. Sixty-five percent (n=15) of the studies addressed only adult women; 21.7% (n=5) addressed adult men and women; 8.6% (n=2) addressed female adolescents and

young females; 4.3% (n=1) addressed only males, and 4.3% (n=1) addressed female adolescents and their mothers. In terms of the location of the studies, it was observed that 65.2% (n=15) of the studies were conducted at tertiary healthcare institutions. Studies were conducted in 13 different provinces in total (Table 2).

In the studies, it was determined that the rate of "Hearing of HPV before" was 3.8% at the lowest and 57.0% at the highest, and the rate of "Hearing of HPV vaccine before" was 2.2% at the lowest and 74.7% at the highest. In the assessed studies, it was reported that the parents' willingness to have their daughters vaccinated with HPV vaccine varied between 14.4% and 68.0%, whereas their willingness to have their sons vaccinated with HPV vaccine varied between 11.0% and 62.0%. In addition, it was reported that the lowest rate of vaccination with HPV vaccine among the participants was 0.3% at the lowest and 6.0% at the highest (Table 2). Two of the reviewed studies investigated the willingness to have education about HPV and its vaccine and it was reported that 69.2% and 95% of the participants were willing to receive health education (Table 3). In nine studies conducted on in HPV vaccine barriers (43.4%), it was reported that the first three barriers identified were lack of knowledge about HPV and vaccine (40.9% to 76.6%), adverse effects concern (0.9% to 64.5%), and the price of HPV vaccine (0.2% to 49.5%), respectively. According to data obtained from the studies, it was observed that the information source of the participants about HPV and vaccine was healthcare personnel at the rate of 12.3% to 72.2%, and media (e.g. TV, internet, newspapers) at a rate of 23.5% to 88.8% (Table 3). In the studies included in the systematic review, it was reported that awareness, knowledge, and positive attitudes on HPV and vaccine increased as the woman's/mother's education level increased in studies that investigated factors in relation to knowledge on HPV and vaccine (60.8%, n=14). In addition, in 17.3% of the studies (n=4), it was reported that awareness, knowledge, and positive attitudes on HPV and vaccine increased in the woman/mother who worked and have high economic level. In this review, it was stated that 82.6% of the studies (n=19) recommended health education, 21.7% (n=5) recommended that more comprehensive and in-depth research should be conducted, and 26.0% (n=6) recommended that policies should be made about vaccine prices and strengthening of primary healthcare services (PHCS) (Table 3).

Summary of evidence

When the reporting properties of 23 cross-sectional studies included in this systematic review were assessed, it was observed that most of them explained the eligibility criteria

in the sample (95.6%) and objective measurements were performed with appropriate statistical analyses and results were reported objectively in all of them. Taking confounding factors under control is quite important in terms of the reliability of the results in cross-sectional studies (22,23). In most of the addressed studies (82.6%), not taking confounding factors under control was considered as a significant limitation in the cross-sectional research design. In addition, using standardized measurement instruments is important in increasing the quality of results obtained in cross-sectional studies (24). In most of the studies reviewed in this study (95.6%), it was determined that standardized valid and reliable measurement instruments were not used. Two valid and reliable scales that assess knowledge, attitude, and beliefs on HPV and vaccine, and which were adapted to Turkish were published in 2016 (25,26). It takes time to publish and announce measurement instruments that are adapted to the culture of a society and use them commonly (27). It was considered that there was a limitation in the studies in terms of using standardized measurement instruments because there were no available standardized measurement instruments until the publication date of valid and reliable HPV and vaccine scales in Turkish, and the measurement instruments were published relatively recently.

In information and awareness studies on HPV and the HPV vaccine that were conducted in developed countries, it was reported that HPV knowledge and awareness were at low-tomoderate levels, and vaccination rates (26%-55%) were not at desired levels, although the willingness for vaccination was high (17,28-34). In studies conducted in developing countries, it was reported that HPV knowledge and awareness and willingness for vaccination were at low-to-moderate levels, and HPV vaccination rates were quite low (13.3%-16.1%) (35-41). In line with the literature, it is considered that the awareness and knowledge level on HPV and the HPV vaccine (3.8%-57.0%) and willingness for vaccination (6.3%-69.0%) and vaccination rates (0.3%-0.6%) are quite low in this systematic review, which addresses community-based studies in Turkey. It was reported that offering consultancy services on HPV performed by healthcare professionals promoted positive attitudes in these countries by increasing awareness and knowledge on HPV (38,42,43). In Turkey, it is anticipated that the fact that HPV has limited coverage in education programs conducted by healthcare professionals is the cause for the awareness and knowledge on HPV and HPV vaccine and therefore vaccination rates not being at desired levels.

Although HPV immunization willingness was high, various barriers made it difficult to raise vaccination rates to the desired level. HPV vaccination barriers in developed countries were listed as doubts about vaccine safety and efficiency, adverse

effect concerns, lack or inconsistency of information about HPV and the HPV vaccine, and the price of the HPV vaccine (29,32,34). In developing countries, HPV vaccine barriers were the lack of awareness of the vaccine, doubting the safety and efficiency of the vaccine, finding it embarrassing to buy the vaccine for sexually transmitted infections, and people thinking that they were not at risk for HPV (35,37,41). In parallel with this, it was determined that the most frequently reported HPV vaccine barriers in studies included in the systematic review were lack of information (40.9% to 76.6%), concerns about the potential adverse effects of the vaccine (0.9% to 64.5%), and the price of the vaccine (0.2% to 49.5%). It was reported that the fact that HPV vaccine was included in the national vaccination schedule in many countries contributed to HPV vaccination in those countries (42). The low HPV vaccination rate obtained in this systematic review could be explained by the fact that HPV vaccine is not included in the national vaccination schedule in Turkey and that vaccine prices are not affordable for the majority of society. In addition, it is anticipated that the fact that healthcare professionals' level of knowledge and awareness is low, common and continuous health education on HPV is not conducted because of the lack of information about HPV vaccination, therefore resulting in the quite low vaccination levels in Turkey.

The most frequent source of healthcare information in developed countries was healthcare professionals, and media (television, internet, newspaper) at a lower rate (17). In developing countries, it was reported that the most frequent source of healthcare information was media, and healthcare professionals at a lower level (36,38). Similarly, in this review, the most frequently preferred source of healthcare information was the media, and healthcare professionals were preferred at a lower rate. In the studies addressed in this review, it was determined that society was willing and ready at a high rate to obtain information on HPV and the HPV vaccine (69.2%, 95%). Correct and reliable healthcare information should be transferred to society only by specialized healthcare professionals (29,44,45). The misinformation sources and broadcasts against vaccination in the media could prevent society from obtaining correct and reliable information about the HPV vaccine (46). For that reason, it is anticipated that healthcare professionals, who are the reliable sources of information on HPV vaccine, can form positive attitudes and behaviors and encourage the society towards vaccination with continuous and common health educations.

In the literature, it was reported that level of knowledge on HPV vaccine increases as people's education levels and income levels increase (28,30,35,39,40,47). In parallel with the literature, it was determined that level of knowledge on HPV vaccine increased as the education level and income level increased in the studies addressed in this systematic review.

In that respect, it was suggested that groups with lower education and income levels should be addressed primarily in programs in relation to HPV and the HPV vaccine. Consistent with the literature, it was determined that most of the studies addressed in this review recommended health education for increasing knowledge, awareness, and positive behaviors towards HPV and the HPV vaccine (48). Systematic, common, and continuous health education programs conducted by professionals in accordance with the culture of the society are the most effective method for creating healthy behaviors (48).

The systematic review was limited to the studies published in EBSCO, Google Scholar, Proquest, PubMed, Springer, and TR index databases for which full texts could be accessed. There full text of two studies were not accessible.

Conclusions

It is considered that conducting common. systematic, and continuous health education programs aimed at both sexes and including both parents, which would increase knowledge and awareness on HPV and the HPV vaccine, and provide positive attitudes, will be effective in protecting people against HPV-related cancers (17,31,33,34,36,38). In addition, it will be an important initiative for the protection of public health that healthcare authorities include HPV vaccines in their immunization programs and that policies encourage acceptance of the vaccine in society in countries where the HPV vaccine is not included in national vaccination schedules. In addition, there is a need for studies with methodologically strong designs that test the methods that will provide positive attitudes towards HPV vaccination in society (30,36,38).

Table 2. Distribution of the community-based cross-sectional studies (n=23)

								Hearing		Willingne	Willingness to vaccination for	ation for
Author	Year	Location of the research	Rage of age	Health institutions	Sample size	Properties of sample	Hearing of HPV (%)	of HPV vaccine (%)	Vaccination rate (%)	Self (%)	Daughter (%)	Son (%)
Adıguzel et al. (49)	2016	Adana	18-65	Tertiary	426	Females	39.4	33.1	*.	42.7	43.7	
Akyuz et al. (43)	2011	Ankara	20-59	Tertiary	229	HPV negative (-) and HPV positive (+) females	HPV (-): 14.7 HPV (+): 43.0	HPV (-): 70.7 HPV (+): 74.7	*,	*.	*,	*
Bebis et al. (50)	2013	Ankara	20-36	Military based	787	Young adult men	29.2	*.	*	*.	*,	*.
Bülbül et al. (51)	2013	Ankara, Kırıkkale, Gaziantep	16-60	Tertiary	1405	Mothers with children of ≤15 years old	*.	46.3	*.	*.	If free of charge: 23.4 Even if paid: 76.6	rge: 23.4 76.6
Çetin et al. (16)	2014	İstanbul	13-18	Tertiary	501	Female adolescents	22.2	11.7	6.0	6.3	*,	*.
Dursun et al. (52)	2009a	Ankara, Adana, Alanya, Konya	17-80	Tertiary	1427	Females	45.0	*.	* '	70.0	64.0	54.0
Dursun et al. (53)	2009b	Ankara, Adana, Alanya, Konya	21-56	Tertiary	618	Mothers with 10-15 year olds children	45.0	*,	*,	0.69	68.0	62.0
Ersan et al. (54)	2012	İzmir	>18	Sex business	239	Sex workers	33.0	19.2	*	*.	*.	*,
Kose et al. (55)	2014	Sakarya	18-55	Tertiary	662	Mothers with children of <pre>≤18 years old</pre>	11.9	16.5	2.0	*.	*.	*.

Ū
=
-=
Ξ
=
\sim
$\mathbf{\mathcal{C}}$
તાં
e
$\overline{}$
9
್ಡಡ

										447.111		
		٠	5	141	-			Hearing		willingne	Willingness to vaccination for	ation ror
Author	Year	Location of the research	Kage of age	Health institutions	Sample size	Properties of sample	Hearing of HPV (%)	of HPV vaccine (%)	vaccination rate (%)	Self (%)	Daughter (%)	Son (%)
Kürtüncü et al. (12)	2018	Zonguldak	>25	Tertiary	100	Mothers with 10-15 years old daughters	57.0	67.0	*.	*	59.0	11.0
Onan et al. (56)	2009	Ankara	15-87	Primary	1808	Females	24.8	24.3	1	17.0	51.1	43.6
Ozan et al. (57)	2011	Bursa	N 18	Tertiary	336	Females	33.6	44.6	*	*,	42.2	22.4
Ozyer et al. (58)	2013	Ankara	9-24	Tertiary	408	Female adolescents and young Females	41.6	*	*	11.2	*,	*,
Önder et al. (59)	2015	Ankara	15-49	Primary	294	Females	24.5	28.2	*.	*,	*	*.
Pınar et al. (60)	2010	Ankara	19-65	Tertiary	471	Females	53.5	57.7	*.	*,	*.	*.
Saylam et al. (61)	2016	Konya	> 18	Tertiary	500	Females	16.6	32.0	2.6	*,	32.0	*.
Seven et al. (62)	2015	Ankara	24-58	School-based	368	Parents with 10- years old children	Mother: 26.9 Father: 25.0	*	*,	*.	Mother: 14.4 Father: 15.5	Mother: 21.6 Father: 22.4
Tas et al. (63)	2016	İstanbul	18-≥65	Tertiary	273	Males and females with anogenital wart lesions	Females: 8.9 Males: 3.8	Females: 2.2 Males: 2.2	*	Females: 66.7 Males: 48.1	*	*.
Tonguc et al. (64)	2012	Elazığ	18-66	Tertiary	945	Females	26.0	21.6	0.9	40.6	36.3	26.0
Turhan et al. (65)	2017	Hatay	>18	Tertiary	1087	Females and males	27.0	23.2	2.7	*	23.5	
Turkol et al. (66)	2009	Malatya	15-49	Primary	417	Females	* 1	46.5	*,	52.4	47.0	*.
Uzuner et al. (67)	2018	İstanbul	> 18	Primary	318	Females and males	*.	49.6	0.3	*,	*,	*,
Oz et al. (68)	2018	Ankara	18-30	School-based	1160	Females and males	43.7	26.6	1.0	45.1	*	*,
*Data on the relevant area we HPV: Human papilloma virus	elevant are	*Data on the relevant area were not found HPV: Human papilloma virus										

_
23
<u>ان</u>
E
S
Ę.
Ĕ
જ
<u>ra</u>
ection
E
se
-Se
cros
ວ
eq
as
ڄ
ity.
H
Ē
Ē
၁
of
ū
Ë
ď
Ī
ist
က
ole

Activation Publication Barriers of HPV vaccine Source of HPV publication publication publication Multingness and vaccine knowledge effect (%) (%) (%) (%) (%) (%) (%) Multingness and vaccine knowledge effect (%) (%) (%) (%) (%) (%) Multingness and vaccine knowledge effect (%) (%) (%) (%) (%) Media (TV) clusted and vaccine knowledge effect (%) (%) (%) (%) Media (TV) clusted and vaccine knowledge effect (%) (%) (%) (%) Media (TV) clusted and vaccine knowledge (%) (%) (%) Media (TV) clusted and vaccine knowledge (%) (%) (%) Media (TV) clusted and vaccine knowledge (%) (%) Media (TV) clusted and vaccine knowledge (%) (%) Media (TV) clusted (%) (%) Media (TV) clusted (%) Clusted (TV) clusted (%) Media (TV) clusted (%) Media (TV) clusted (%) Media (TV) clusted (%) Media (TV) clusted (%) Media (TV) clusted (%) Media (TV) clusted (%) Media (TV) clusted (%) Media (TV) clusted (%) Media (TV) clusted (%) Media (TV) clusted (%) Media (TV) clusted (%) Media (TV) clusted (%) Media (TV) clusted (%) Media (TV) clusted (%) Media (TV) clusted (%) Media (TV) clusted (TV) clusted (%) Media (TV) clusted (TV) cl							(22 - 22)					
Part Part	A 41.	Barriers of I	HPV vaccin	ie.	Source of HF knowledge	Λ	Willingness	Factors in relat and vaccine kn	tion to HPV towledge	Suggestions	S	
1. 2. 2. 3. 40.4 39.1 39.1 3. 40.4 39.1 39.1 3. 40.4 39.1 3. 40.4 39.1 3. 40.4 39.1 3. 40.4 39.1 3. 40.4 39.1 3. 40.4 39.1 3. 40.4 39.1 3. 40.4 3. 40.4 3. 3. 40.4 3. 3. 40.4 3. 3. 40.4 3. 3. 3. 40.4 3. 3. 3. 40.4 3. 3. 3. 3. 40.4 3. 3. 3. 3. 3. 40.4 3. 3. 3. 3. 3. 3. 40.4 3. 3. 3. 3. 3. 3. 3.	Aumor, publication year	Lack of knowledge (%)	Adverse effect (%)	Price (%)	Healthcare personnel (%)	Media (TV, internet, newspaper) (%)	education about HPV (%)	Education level	Working/ economic level	Education	Research	Policy
-* HPV (+): 32.2 HPV (+): 62.7 -* As the level of education increases, increa	Adiguzel et al. (49) 2016	*,	*,	*.	40.4	39.1	*,	As the level of education increases, knowledge and awareness level increase (p<0.001)	*.	Health	*.	*:
As the level of education increases, smowledge level increases, smowledge level increases (p < 0.001) *** 44.4 *** *** *** *** *** *** *** ***	Akyuz et al. (43) 2011	*	*	*.		HPV (-): 86.8 HPV (+): 62.7	*:	*.	*.	Health education	*.	*.
As the level of education increases, -* 44.4 -* -* -* -* As the level of education increases, -* (p < 0.001) As mothers' education level increases -* (p < 0.001) As mothers' education level increases -* -* -* (p < 0.001) As mothers' education level increases -* -* -* (p < 0.001) As mothers' education level increases -* -* (p < 0.001) (p < 0.001) -* -* -* -* -* (p < 0.001) -* -* -* -* -* -* -* -	Bebis et al. (50) 2013	*,	*,	*,	³⁶ ,	³⁶ ,	** ₁	As the level of education increases, knowledge level increases (p<0.001)	*,	*,	Comprehensive research	*,
40.9 16.4 26.4 17.1 59.4 -* mothers' education level increases, knowledge level increases (p<0.001) -* -* -* -* -* -* -* -* -* -* knowledge level increases (p<0.001) -* -* -* -* -* -* -* -* knowledge level increases (p<0.001) -* -* -* -* -* -* -* knowledge level increases (p<0.001) -* -* -* -* -* -* -* -* -* -* -* -* -* -	(51) 2013	*,	*,	44.4	⁹⁶ ,	**,	**,	As the level of education increases, knowledge level increases (p<0.001)	*,	Health education	Comprehensive research	Wages policy
As mothers' education level increases, "* knowledge level increases (p < 0.001)	Çetin et al. (16) 2014	40.9	16.4	26.4	17.1	59.4	*,	As mothers' education level increases, knowledge level increases (p<0.001)	*,	Health education	Comprehensive research	*,
*, *, *, *, *, *, *, *, *, *, *, *, *, *	Dursun et al. (52) 2009	*,	*,	*,	*,	*,	*,	As mothers' education level increases, knowledge level increases (p<0.001)	*,	Health education	Comprehensive research	Vaccination policy
	Dursun et al. (53) 2009	*,	*,	*,	*,	*,	*,	*,	*,	*,	Comprehensive research	*,

Table 3. Continued	ntinued										
A *** \$4	Barriers of HPV vaccine	HPV vaccir	1e	Source of HPV knowledge	ρV	Willingness	Factors in relation to HPV and vaccine knowledge	tion to HPV cowledge	Suggestions	90	
Author, publication year	Lack of knowledge (%)	Adverse effect (%)	Price (%)	Healthcare personnel (%)	Media (TV, internet, newspaper) (%)	education about HPV (%)	Education level	Working/ economic level	Education	Research	Policy
Ersan et al. (54), 2012	**	*,	*	*,	₩.	*.	There is no relation between HPV knowledge and education level (p>0.001)	*,	Health education	*	*
Kose et al. (55), 2014	**	*,	* '	27.1	61.2	**	As mothers' education level increases, knowledge level increases (p<0.001)	As the level of economic status increases, awareness level increase (p<0.001)	Health	**,	*,
Kürtüncü et al. (12), 2018	0.99	*,	26.0	*,	*,	95.0	As the level of education increases, knowledge level increases (p<0.001)	There is relation to work status and level of knowledge (p<0.001)	Health education	*.	Strengthening of PHCS+
Onan et al. (56), 2009	*.	1.5	*	*	*	*	*.	*,	Health education	*,	*
Oz et al. (68) 2018	9.92	32.3	*	14.0	61.0	*	*.	*.	Health education	*,	*
Ozan et al. (57), 2011	36 1	*,	* '	*,	*,	*,	As the level of education increases, knowledge level increases (p<0.001)	There is relation to work status and level of knowledge (p<0.001)	Health education	*,	*,
Ozyer et al. (58), 2013	*,	0.9	0.2	25.9	23.5	*	*.	*,	Health education	*.	*,

A £1. o	Barriers of HPV vaccine	HPV vaccii	ne	Source of HPV knowledge	Α	Willingness	Factors in relation to HPV and vaccine knowledge	n to HPV dedge	Suggestions	90	
Author, publication year	Lack of knowledge (%)	Adverse effect (%)	Price (%)	Healthcare personnel (%)	Media (TV, internet, newspaper) (%)	education about HPV (%)	Education level	Working/ economic level	Education	Research	Policy
Önder et al. (59), 2015	*,	*.	*,	72.2	88.8	** ₁	As the level of education increases, knowledge level increases (p<0.001)	*	*,	*,	Strengthening of PHCS+
Pmar et al. (60), 2010	*,	*,	*,	25.7	42.9	** ₁	As the level of education increases, knowledge level increases (p<0.001)	*,	Health education	*,	*
Saylam et al. (61), 2016	*	*,	*.	50	25.6	69.2	*,	*	Health education	*.	*,
Seven et al. (62), 2015	67.2	64.5	6.4	*.	*.	*.	*,	*	Health education	*.	*
Tas et al. (63) 2016	*	*.	*,	*,	*,	*.	*.	*	*.	*,	*.
Tonguc et al. (64), 2012	*,	*,	49.5	*,	**,	*,	As the level of education increases, knowledge level increases (p<0.001)	*,	Health education	*,	Wages policy
Turhan et al. (65), 2017	*,	5.9	*,	*,	⁹⁶ ,	** ₁	As the level of education increases, knowledge level increases (p<0.001)	*	Health education	*,	**
Turkol et al. (66), 2009	*;	*;	*,	*,	63.6	*,	As the level of education increases, knowledge level increases (p<0.001)	As the level of economic status increases, awareness level increase (p<0.001)	Health education	*,	*,

Policy

Research

Education

economic Working/

level

Suggestions

relation to HPV

ne knowledge

Strengthening

*

education Health

Table 3. Continued	ntinued						
1	Barriers of HPV vaccine	HPV vaccin	e	Source of HPV knowledge	>	Willingness	Factors in relatio and vaccine knov
Aumor, publication year	Lack of Adverse knowledge effect (%)	Adverse effect (%)	Price (%)	Healthcare personnel (%)	Media (TV, in the deduction internet, internet	to nave education about HPV (%)	Education level
							As the level
							of education
Uzuner et al.	47.1	9.1	*	C L	640	*	increases,
(67), 2018	47.1	0.1	:	0.00	0.4.0		knowledge
							level increases
							(p<0.001)

+PHCS: Primary healthcare services, HPV: Human papilloma virus *Data on the relevant area were not found

Peer-review: Externally peer-reviewed.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

- 1. Allison M, Musser B, Satterwhite C, Ault K, Kelly P, Ramaswamy M. Human Papillomavirus Vaccine Knowledge and Intention Among Adult Inmates in Kansas, 2016-2017. Am J Public Health 2018; 108: 1000-2.
- 2. Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, et al. ICO/IARC Information centre on HPV and cancer. Human Papillomavirus and Related Diseases in Turkey, Summary Report, Retrewied: 10 April 2019.
- 3. Portillo-Romero AJ, León-Maldonado L, Allen-Leigh B, Brown B, Magis C, García-Fuentes NB, et al. HPV vaccine acceptance is high among adults in Mexico, particularly in people living with HIV. Salud Publica Mexico 2018; 60:
- 4. Flagg EW, Torrone EA, Weinstock H. Ecological association of Human Papilloma Virus vaccination with cervical dysplasia prevalence in the United States, 2007-2014. Am J Public Health 2016; 106: 2211-8.
- 5. Lowy DR. HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. J Clin Invest 2016; 126:
- 6. Viens LJ, Henley SJ, Watson M, Markowitz LE, Thomas CC, Thompson TD, et al. Human papillomavirus-associated cancers-United States, 2008-2012. Centers for Disease Control and Prevention MMWR 2016; 65: 661-6.
- Bray F. Ferlay J. Soeriomataram J. Siegel RL, Torre LA, Jemal A, Global Cancer Statistics 2018: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
- Donadiki EM, Jiménez-García R, Hernández-Barrera V, Sourtzi P, Carrasco-Garrido P, López de Andrés A, et al. Health Belief Model applied to noncompliance with HPV vaccine among female university students. Public Health 2014; 128: 268-73.
- 9. Apaydin KZ, Fontenot HB, Shtasel DL, Mayer KH, Keuroghlian AS. Primary care provider practices and perceptions regarding hpv vaccination and anal cancer screening at a boston community health center. J Community Health 2018; 43:
- 10. Kirby T. FDA approves new upgraded Gardasil 9. Lancet Oncol 2015; 16: e56.
- 11. Btoush RM, Brown DR, Fogarty S, Carmody DP. Initiation of Human Papilloma Virus vaccination among predominantly minority female and male adolescents at Inner-city community health centers. AM J Public Health 2015; 105: 2388-96.
- 12. Kürtüncü M, Arslan N, Alkan I, Bahadır Ö. 10-15 yaş arası kız çocuğu olan annelerin rahim ağzı kanseri ve HPV aşısı konusunda bilgi, tutum ve davranışları. Int J Hum Sci 2018; 15: 1072-85.
- 13. European Medicines Agency (EMA), Annual report 2015. Retrewied: 28 March 2019.
- 14. European Centre for Disease Prevention and Control. Introduction of HPV vaccines in EU countries - an update. Stockholm: ECDC; 2012. Retrievied: 28 March 2019.
- 15. Gülcü S, Arslan S. Çocuklarda aşı uygulamaları: Güncel bir gözden geçirme. Düzce Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi 2018; 8: 34-43.
- 16. Çetin O, Verit FF, Keskin S, Zebitay AG, Deregözü A, Usta T, et al. Knowledge levels of adolescent girls about Human Papilloma Virus and its vaccine. Türk Pediatri Ars 2014; 49: 142-7.
- 17. Giambi C, D'Ancona F, Del Manso M, De Mei B, Giovannelli I, Cattaneo C, et al. Exploring reasons for non vaccination against Human Papilloma Virus in Italy. BMC Infect Dis 2014; 14: 1-9.
- 18. Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to Human Papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr 2014; 168: 76-82.

- Nahcivan N, İncirkuş K. Türkiye'de hemşirelik dergilerinde yayınlanan sistematik derlemelerin raporlama özellikleri. Hemşirelikte Eğitim ve Araştırma Dergisi 2018; 15: 106-16.
- Zeng X, Zhang Y, Kwong JSW, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med 2015; 8: 2-10.
- The Joanna Briggs Institute (JBI), (2017) Critical Appraisal tools for use in JBI Systematic Reviews, JBI Critical Appraisal Checklist for Analytical Cross Sectional Studies, Retrewied: 25 February 2019.
- Song JW, Chung KC. Observational studies: cohort and case-control studies. Plast Reconstr Surg 2010; 126: 2234-42.
- 23. Pearce N, Checkoway H, Kriebe D. Bias in occupational epidemiology studies. Occup Environ Med 2007; 64: 562-8.
- 24. Girard JM, Cohn JF. A primer on observational measurement. Assessment 2016; 23: 404-13.
- 25. Guvenc G, Seven M, Akyuz A. Health belief model scale for Human Papilloma Virus and its vaccination: adaptation and psychometric testing. J Pediatr Adolesc Gynecol 2016; 29: 252-8.
- Özdemir E, Kısa S. Validation of the Turkish cervical cancer and Human Papilloma Virus awareness questionnaire. Int Nurs Rev 2016: 63: 465-72.
- 27. Cha ES, Kim KH, Erlen JA. Translation of scales in cross-cultural research: issues and techniques. J Adv Nurs 2007; 58: 386-95.
- 28. Dodd RH, McCaffery KJ, Marlow LAV, Ostini R, Zimet GD, Waller J. Knowledge of Human Papillomavirus (HPV) testing in the USA, the UK and Australia: an international survey. Sexually Transmitted Infections 2014; 90: 201-7.
- 29. Fernandes R, Potter BK, Little J. Attitudes of undergraduate university women towards HPV vaccination: a cross-sectional study in Ottawa, Canada. BMC Womens Health 2018; 18: 1-9.
- Marlow LAV, Zimet GD, McCaffery KJ, Ostini R, Waller J. Knowledge of Human Papillomavirus (HPV) and HPV vaccination: An international comparison. Vaccine 2013; 31: 763-9.
- 31. Jelastopulu E, Fafliora E, Plota A, Babalis V, Bartsokas C, Poulas K, et al. Knowledge, behaviours and attitudes regarding HPV infection and its prevention in female students in West Greece. Eur Rev Med Pharmacol Sci 2016; 20: 2622-9.
- 32. Ojeaga A, Alema-Mensah E, Rivers D, Azonobi I, Rivers B. Racial disparities in HPV-related knowledge, attitudes, and beliefs Among African American and white women in the USA. J Cancer Educ 2019; 34: 66-72.
- 33. Sherman SM, Nailer E. Attitudes towardsand knowledge about Human Papilloma Virus (HPV) and the HPV vaccination in parents of teenage boys in the UK. PLoS One 2018; 13: e019580.
- 34. Walsh CD, Gera A, Shah M, Sharma A, Powell JE, Wilson S. Public knowledge and attitudes towards Human Papilloma Virus (HPV) vaccination. BMC 2008; 8: 1-9.
- 35. Al-Dubai SAR, Alshagga MA, Al-Naggar RA, Al-Jashamy K, Baobaid MF, Tuang CP, et al. Knowledge, attitudes and barriers for Human Papilloma Virus (HPV) vaccines among Malaysian women. Asian Pac J Cancer Prev 2010; 11: 887-92.
- 36. Balla BC, Terebessy A, Tóth E, Balázs P. Young Hungarian students' knowledge about HPV and their attitude toward HPV vaccination. Vaccines 2017; 5: 1-9.
- 37. Chang IJ, Huang R, He W, Zhang SK, Wang SM, Zhao FH, et al. Effect of an educational intervention on HPV knowledge and vaccine attitudes among urban employed women and female undergraduate students in China: a cross-sectional study. BMC Public Health 2013; 13: 1-8.
- 38. Chiang VCL, Wong HT, Yeung PCA, Choi YK, Fok MSY, Mak OI, et al. Attitude, acceptability and knowledge of HPV vaccination among

- local university students in Hong Kong. Int J Environ Res Public Health 2016; 13: 486.
- 39. Hanisch R, Gustat J, Hagensee ME, Baena A, Salazar JE, Castro MV, et al. Knowledge of Pap screening and Human Papillomavirus among women attending clinics in Medellín, Colombia. Int J Gynecol Cancer 2007; 18: 1020-6.
- Saha A, Chaudhury AN, Bhowmik P, Chatterjee R. Awareness of cervical cancer among female students of premier colleges in Kolkata, India. Asian Pac J Cancer Prev 2010; 11: 1085-90.
- 41. Wong LP. Knowledge and attitudes about HPV infection, HPV vaccination, and cervical cancer among Rural Southeast Asian women. Int J Behav Med 2011; 18: 105-11.
- 42. Chan ZCY, Chan TS, Kui Ng K, Wong ML. A systematic review of literature about women's knowledge and attitudes toward Human Papillomavirus (HPV) Vaccination. Public Health Nurs 2012; 29: 481-9.
- Akyuz A, Yılmaz C, Yenen MC, Yavan T, Kılıc A. Women's awareness of the Human Papilloma Virus and related health problems. J Adv Nurs 2011; 67: 2703-12.
- Dempsey AF, Pyrznawoski J, Lockhart S, Barnard J, Campagna EJ, Garrett K, et al. Effect of a health care professional communication training intervention on adolescent Human Papillomavirus vaccination a cluster randomized clinical trial. JAMA Pediatr 2018; 172: e180016.
- 45. Sherris J, Friedman A, Wittet S, Davies P, Steben M, Saraiya M. Education, training, and communication for HPV vaccines. Vaccine 2006; 24: 210-8.
- 46. Hanley SJB, Yoshioka E, Ito Y, Kishi R. HPV vaccination crisis in Japan. The Lancet 2015; 385: 2571.
- 47. Strohl AE, Mendoza G, Ghant MS, Cameron KA, Simon MA, Schink JC, et al. Barriers to prevention: knowledge of HPV, cervical cancer, and HPV vaccinations among African American women. Am J Obstet Gynecol 2015; 212: e1-e5.
- 48. Maurer FA, Smith CM. (edts) Community/Public Health Nursing Practice. Fourth edition, Canada: Saunders Elsevier 2009; p. 511.
- 49. Adıguzel FI, Adıguzel C, Seyfettinoglu S, Hurriyetoglu S, Kazgan H, Saygili-Yilmaz ES, et al. Doğu Akdeniz bölgesinde bir 3.basamak referans merkezinin kadın hastalıkları ve doğum polikliniğine başvuran hastalarda HPV aşısı farkındalığı ve kabul edilebilirliği. Bakırköy Tıp Dergisi 2016; 12: 136-9.
- 50. Bebis H, Gülesen A, Ortabag T. Knowledge and attitudes of Turkish young adult men regarding HPV and HPV related diseases. J Behav Health 2013; 2: 52-8.
- 51. Bülbül S, Yalçın S, Çöl Arazi N, Turgut M, Ekici İ, Doğan A, et al. Anadolu'da 0-15 yaş çocuk annelerinin rahim ağzı kanseri ve Human Papilloma Virüs aşılaması hakkındaki düşünceleri. Türkiye Çocuk Hastalıkları Dergisi 2013; 7: 73-8.
- 52. Dursun P, Altuntas B, Kuscu E, Ayhan A. Women's knowledge about human papillomavirus and their acceptance of HPV vaccine. Aust N Z J Obstet Gynaecol 2009; 49: 202-6.
- 53. Dursun P, Kuşçu E, Zeyneloğlu HB, Yanık FB, Ayhan A. 10-15 yaş arası adolesan çocuğu olan annelerin HPV aşısı hakkındaki bilgi ve tutumları. Turk J Obstet Gynecol 2009; 6: 206-10.
- 54. Ersan G, Köse Ş, Güneş H, Özkan M. Knowledge and awareness of female sex workers towards Human Papillomavirus infection in Turkey. Cent Eur J Public Health 2012; 20: 219-22.
- 55. Kose D, Erkorkmaz U, Cinar N, Altinkaynak S. Mothers' knowledge and attitudes about HPV vaccination to prevent cervical cancers. Asian Pac J Cancer Prev 2014; 15: 7263-6.
- Onan A, Ozkan S, Korucuoglu U, Aksakal N, Taskiran C, Aygun R, et al. Knowledge on and attitude toward Human Papillomavirus infection and its vaccine in a Turkish subpopulation. Turkiye Klinikleri J Med Sci 2009; 29: 594-8.

- 57. Ozan H, Çetinkaya Demir B, Atik Y, Gümüş E, Özerkan K. Kadın hastalıkları ve doğum polikliniğine başvuran Hastaların Human Papilloma Virüs ve HPV aşısı hakkındaki bilgi düzeylerinin belirlenmesi. Uludağ Üniversitesi Tıp Fakültesi Dergisi 2011; 37: 145-8.
- 58. Ozyer S, Uzunlar O, Ozler S, Kaymak O, Baser E, Gungor T, Mollamahmutoglu L. Awareness of Turkish female adolescents and young women about HPV and their attitudes towards HPV vaccination. Asian Pac J Cancer Prev 2013; 14: 4877-81.
- 59. Önder Ö, Dicle M, Gülmez H, Aypak C, Akbıyık Dİ, Görpelioğlu S. Birinci basamağa başvuran doğurganlık çağındaki kadınların Human Papilloma Virus (HPV) ve HPV aşısı hakkındaki bilgi düzeyleri. Cukurova Medical Journal 2015; 40: 517-24.
- 60. Pınar G, Topuz Ş, Arı Ş, Algıer L, Kaya N, Doğan EN. Başkent Üniversitesi Ankara Hastanesi kadın hastalıkları ve doğum polikliniğine başvuran kadınların HPV aşısı ve serviks kanseri ile ilgili bilgi düzeyleri. Türk Jinekolojik Onkoloji Dergisi 2010; 13: 11-8.
- 61. Saylam Kurtipek G, Göksin Cihan F, Ataseven A, Özer İ, Can Turhan Z. On sekiz yaş üzeri kadınların genital verru, servikal kanser ve Human Papilloma virüs aşısı hakkında bilgi, tutum ve davranışları. Turk J Dermatol 2016; 10: 105-9.
- Seven M, Güvenç G₃ Şahin E, Akyüz A. Attitudes to HPV vaccination among parents of children aged 10 to 13 years. J Pediatr Adolesc Gynecol 2015; 28: 382-6.

- 63. Tas B, Turker K, Balci E. Risk-factors and awareness of HPV in Turkish people with anogenital warts in Bagcilar district: a crosssectional study. Arch Iran Med 2016; 19: 719-23.
- 64. Tonguc E, Gungor T, Var T, Kavak E, Yucel M, Uzunlar O. Knowledge about HPV, relation between HPV and cervix cancer and acceptance of HPV vaccine in women in Eastern region of Turkey. J Gynecol Oncol 2013; 24:7-13.
- 65. Turhan E, Cetin S, Cetin M, Abacigil F. Awareness and knowledge levels of 18-year-old and older individuals regarding Human Papillomavirus (HPV) and HPV Vaccine in Hatay, Turkey. J Cancer Educ 2019; 34: 234-41.
- 66. Turkol E, Gunes G, Ozen G, Omac M. Kadınların serviks kanseri, pap smear ve hpv aşısı hakkında bilgi tutum ve davranışları. E-Journal of New World Sciences Academy 2009; 4: 67-74.
- Uzuner A, Arabacı Ş, Yüceel Aİ, Kocatürk AC, Kaynar E, Khan A. Erişkinlerin erişkin aşıları hakkındaki bilgi, tutum ve davranışları. Turkish Journal of Family Medicine and Primary Care 2018; 12: 215-25.
- 68. Oz M, Cetinkaya N, Apaydin A, Korkmaz E, Bas S, Ozgu E, et al. Awareness and knowledge levels of Turkish college students about Human Papilloma Virus infection and vaccine acceptance. J Cancer Educ 2018; 33: 260-8.